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Abstract 
Background: Several systemic therapeutic options exist for metastatic castrate-
sensitive prostate cancer (mCSPC). Circulating tumour DNA (ctDNA) can molecularly 
profile metastatic castration-resistant prostate cancer (mCRPC) and can influence 
decision-making, but remains untested in mCSPC. 
Objective: To determine ctDNA abundance at de novo mCSPC diagnosis and whether 
ctDNA provides complementary clinically-relevant information to a prostate biopsy. 
Design, Setting, and Participants: We collected plasma cell-free DNA (cfDNA) from 
53 newly diagnosed patients with mCSPC and, where possible, during treatment. 
Targeted sequencing was performed on cfDNA and DNA from diagnostic prostate 
tissue. 
Results and Limitations: Median ctDNA fraction was 11% (range 0-84) among 
untreated patients but lower (1.0%, range 0-51) in patients after short term (median 22 
days) androgen deprivation therapy (ADT). TP53 mutations and DNA repair defects 
were identified in 47% and 21% of the cohort, respectively. Concordance for mutation 
detection in matched samples was 80%. Combined ctDNA and tissue analysis identified 
potential driver alterations in 94% of patients, whereas ctDNA or prostate biopsy alone 
was insufficient in 19 cases (36%). Limitations include the use of a narrow gene panel 
and undersampling of primary disease by prostate biopsy. 
Conclusions: ctDNA provides additional information to a prostate biopsy in men with de 
novo mCSPC, but ADT rapidly reduces ctDNA availability. Primary tissue and ctDNA 
share relevant somatic alterations, suggesting that either are suitable for molecular 
subtyping in de novo mCSPC. The optimal approach for biomarker development should 
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utilize both a tissue and liquid biopsy at diagnosis, as neither captures clinically-relevant 
somatic alterations in all patients. 
Patient summary: In men with advanced prostate cancer, tumour DNA shed into the 
bloodstream can be measured by a blood test. The information from this test provides 
complementary information to a prostate needle biopsy and could be used to guide 
management strategies. 
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Introduction 
De novo metastatic disease represents 5-10% of prostate cancer (PCa) diagnoses but 
contributes to almost 50% of PCa related deaths [1,2]. The incidence of de novo 
metastatic diagnosis is rising, potentially related to improved imaging modalities and 
decreased prostate specific antigen (PSA) screening [3,4]. Historically, affected men 
were managed with systemic androgen deprivation therapy (ADT) alone, but recent 
phase III data supports treatment combination with taxane chemotherapy or androgen 
receptor (AR) targeted therapy in high burden disease [5–8]. Other targeted therapies 
such as poly (ADP-ribose) polymerase inhibitors (PARPi) are also being tested in 
metastatic castration-sensitive prostate cancer (mCSPC). As such, there is increasing 
interest in the potential for tumour molecular features to help guide therapy choice. 
The majority of patients with de novo mCSPC will not undergo surgical management of 
their primary tumour, and metastatic biopsy is not routine. The only source of tissue is 
typically the diagnostic prostate biopsy. In some cases, diagnosis is based solely on 
clinical parameters such as exceptionally elevated PSA and concurrent radiographic 
bone lesions. Although next-generation sequencing of formalin-fixed paraffin-embedded 
(FFPE) tissue-derived DNA is now routine, it is unknown whether tumour cells obtained 
from prostate biopsy are representative of synchronous metastatic deposits. 
Plasma circulating tumour DNA (ctDNA) is a promising minimally-invasive biomarker in 
progressing metastatic castration-resistant prostate cancer (mCRPC) [9–11]. The 
fraction of ctDNA as a proportion of total cell-free DNA (cfDNA) can approach 90% in 
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mCRPC [10,12]. High ctDNA levels reflect proliferative disease and poor prognosis, and 
ctDNA-based mutational and copy number profiles are consistent with matched 
metastatic tissue [10,12,13]. However, plasma ctDNA is largely unexplored in mCSPC; it 
remains unclear whether acute ADT impacts ctDNA levels—a relevant question 
because de novo mCSPC patients may initiate ADT before the decision for treatment 
intensification (e.g. with chemotherapy). In this study, our objective was to determine 
ctDNA abundance at de novo mCSPC diagnosis and establish the degree to which 
molecular subtyping obtained from prostate biopsy tissue and ctDNA are 
complementary. 
Patients and Methods 
Clinical cohort 
We prospectively enrolled 53 men diagnosed with de novo mCSPC at Vancouver 
General Hospital / University of British Columbia (UBC) Department of Urologic 
Sciences and British Columbia Cancer Agency from June 2014 to March 2018. A 
confirmatory transrectal ultrasound (TRUS) guided prostate biopsy was performed in 50 
patients. Diagnoses were established by histology, PSA levels, and radiographic 
imaging (computed tomography and/or bone scan). All patients underwent blood 
collection for ctDNA analysis within 50 days of diagnosis. Where possible, blood was 
obtained at follow-up appointments. Three additional men with de novo mCSPC were 
enrolled at Tampere University Hospital from October 2017 to June 2018. Study 
approval was granted by the UBC Clinical Research Ethics Board (certificates 
H18-00944, H16-00934 and H09-01628) and the Regional Ethics Committee of 
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Tampere University Hospital (certificate R03203). Written informed consent was 
obtained from all participants prior to enrollment. 
Sample processing, DNA sequencing, and bioinformatics 
Blood and tissue processing were performed as previously described (Supplementary 
Methods) [10,14,15]. We employed an established targeted sequencing strategy 
capturing the exons of 73 PCa driver genes in cfDNA and tissue samples [10], modified 
by the inclusion of four bp molecular barcodes to the index sequence for cfDNA 
libraries. Sequence data analysis, including identification of somatic mutations and copy 
number alterations was performed according to published protocols [10]. ctDNA fraction 
was estimated based on somatic mutation allele fractions and leveraged matched tissue 
sample mutations in cases with low ctDNA fractions (Supplementary Methods). De-
identified sequencing data was deposited to the European Genome-phenome Archive 
(EGA) under study identifier (EGAS00001003351). 
Outcome measures 
Castration-resistance was defined according to Prostate Cancer Clinical Trials Working 
Group 3 guidelines [16]. Time to progression and follow-up were calculated from start of 
ADT. Survival fractions were estimated using the Kaplan-Meier method and differences 
between groups were identified using the logrank test. All hypothesis tests were two-
tailed and used a 5% significance threshold. Hazard ratios (HR) were calculated using 
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Cox proportional hazards regression with binary covariates (dichotomized at cohort 
median), using “survival” package version 2.41.3 in R version 3.5.0. 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Results 
Patient characteristics are provided in Table 1 and Supplementary Table 1. Plasma 
cfDNA sequencing was successful in 52/53 patients (median depth 927x; 
Supplementary Table 2). 48/53 patients had diagnostic tissue available. Of the five 
patients without tissue, three had no local biopsy performed (clinical diagnoses only), 
while two had no remaining tumour after pathology slides were prepared. Tissue 
sequencing was successful in all 48 patients (median depth 189x). 
Androgen deprivation rapidly reduces ctDNA abundance 
For 35/53 patients, plasma cfDNA was collected prior to ADT initiation; 74% (26/35) of 
these had detectable ctDNA (fraction range 2.0-84%) (Fig. 1A; Supplementary Table 
3), similar to the proportion of mCRPC patients that have detectable ctDNA with our 
approach [10,12]. 18 patients received 1-49 days of ADT (degarelix or goserelin plus 
bicalutamide) prior to cfDNA collection (median 22 days) (Fig. 1A); only 10 of 17 (59%) 
with successfully sequenced cfDNA had detectable ctDNA, and ctDNA fractions were 
significantly lower than in treatment-naïve patients (mean 6.7% versus 23%, median 
1.0% versus 11%; p=0.02, ranksum test). The reduction in ctDNA fractions was more 
pronounced after one week of ADT. 
For six patients with detectable ctDNA at diagnosis, we obtained follow-up plasma 
samples within four months of ADT initiation. In 5/6 patients, ctDNA was undetectable at 
follow-up (Fig. 1B). In one patient, ctDNA fraction increased from 50% to 70% between 
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days 4 and 40 on ADT, despite a PSA decline. This patient subsequently began 
chemotherapy and ctDNA was undetectable in the third collection (102 days after ADT 
initiation). To confirm the overall trend, we examined serial samples from three patients 
collected within one week of commencing ADT. A clear reduction in ctDNA fraction was 
observed one day after ADT initiation. By day seven, ctDNA fractions were reduced to 
near zero (Fig. 1B; Supplementary Fig. 1). 
Comprehensive diagnostic imaging data was available for 32 patients. All eight patients 
with liver or lung lesions (including three patients exposed to ADT) demonstrated 
detectable ctDNA, significantly higher than the remainder of the cohort with confirmed 
lymph node and/or bone metastases only (14/26, p=0.03, Fisher’s exact test) (Fig. 1C). 
3/8 patients with visceral metastases had intraductal features in their prostate biopsy. 
We observed no relationship between ctDNA fraction and PSA, Gleason grade, or age 
(Fig. 1C). 
Aggressive genomic features with frequent TP53 mutations and DNA repair 
defects 
Combining somatic information from ctDNA and tumour tissue revealed a landscape 
similar to mCRPC [17], albeit without AR gene alterations (Fig. 2A; Supplementary 
Fig. 2; Supplementary Tables 4 and 5). TP53 mutations were identified in almost half 
the cohort (triple the frequency in localized disease [18]) while a further 11 patients 
without TP53 mutations harboured gene deletions. Eleven patients (21%) exhibited 
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truncating mutations within DNA damage repair (DDR) genes, including four patients 
with BRCA2 mutations (two germline). We identified two patients with CDK12 mutations 
and copy number profiles with multiple  amplifications (e.g. CDK6, CCND1; 
Supplementary Fig. 3) consistent with the CDK12-associated tandem duplication 
genotype [19,20]. We also identified truncating mutations in RAD51C and ATR, but in 
neither case was deletion or mutation of the second allele evident (unlike all deleterious 
BRCA2 and ATM mutations; Supplementary Fig. 4). We identified one case with an 
MSH2 frameshift mutation (and deletion of the second allele) and a high tumour 
mutation burden consistent with mismatch repair (MMR) deficiency. 
ctDNA and tissue biopsy provide complementary insight to driver gene status 
Neither tumour tissue nor plasma cfDNA sequencing in isolation was sufficient to 
capture somatic information from all patients. We restricted analyses to the 35 patients 
with no prior ADT, thereby avoiding any confounding influence on ctDNA abundance. 
This subset included five patients (14%) where either a tissue biopsy was not 
performed, or the biopsy core lacked somatic alterations (Fig. 2B). Importantly, in four of 
these patients somatic alterations were detected in ctDNA. There were also four ADT-
naïve patients where, despite informative tumour tissue, the ctDNA fraction proved 
higher than the tumour tissue cellularity (as assessed by the same bioinformatic 
approach). Conversely, ten ADT-naïve samples had detectable ctDNA but at levels 
between 2 and 15%, where low-level gene copy number changes are challenging to 
resolve. The majority of these patients had tumour tissue cellularity sufficient for copy 
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number analysis (Fig. 2B). Finally, nine ADT-naïve samples had no ctDNA detected with 
our approach; tissue biopsy profiling better serves these patients. Across the entire 
cohort, no somatic information was obtained from either approach in only three cases 
(6%). 2/3 patients had received prior ADT at time of cfDNA collection, compromising 
ctDNA abundance. 
TP53 alterations are linked to poor prognosis and may represent an important variable 
to capture at initial diagnosis [10,21]. For ADT-naïve patients, over half (9/17) of the 
non-silent TP53 mutations were missed by either tissue biopsy profiling or cfDNA 
sequencing, primarily due to failure of one approach to capture any somatic information, 
as described above (Fig. 2C). For DDR gene mutations, 9/13 were identified in both 
tissue and ctDNA (Fig. 2D). However, the MSH2 truncating mutation and accompanying 
hypermutation was only identified in the ctDNA of patient 11050; there was no evidence 
for this clone in matched tumour tissue, and the Gleason grade group of 1 suggests that 
the prostate biopsy undersampled disease. Three DDR gene mutations present in 
tumour tissue were not identified by cfDNA profiling; two alterations were in patients 
exposed to prior ADT at sample collection, confounding ctDNA detection. One patient 
with an ATM truncating mutation and monoallelic deletion in tissue had no detectable 
ctDNA despite being ADT-naïve and carrying a high plasma cfDNA concentration (16.7x 
cohort median). He had marrow infiltration and pancytopenia at time of blood collection, 
suggesting that ctDNA signal may have been diluted by elevated non-malignant cfDNA. 
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It is unclear whether a primary tissue sample is representative of metastatic lesions in 
patients with de novo mCSPC. Here, mutational profiles of de novo mCSPC primary 
tissue and ctDNA were similar in cases where both approaches yielded sufficient 
tumour content for comparison. Among the 26 cases with somatic mutations detected in 
both tissue and ctDNA (excluding the MMR deficient case), 51/64 (80%) were identified 
in both compartments (Supplementary Table 4; Supplementary Figs. 2, 5 and 6). Of 
the 13 mutations detected in only one sample, seven were unique to ctDNA, while six 
were found only in tissue. 
Majority of alterations in CSPC are shared at CRPC progression 
Follow-up for the cohort was 11 months. At time of writing, 18 patients had progressed 
with CRPC (including two with neuroendocrine PCa); this included 7/11 (63%) patients 
harbouring DDR gene mutations (median time to progression 7.3 months (95% CI: 3.2 - 
18.7) compared to not reached (95% CI: 10.6 - not reached) for the remainder of the 
cohort (p=0.01, logrank test; Fig. 3A-B). Note that time to CRPC should be interpreted 
in the context of variable treatment regimens (Table 1). DDR gene status did not remain 
significant in multivariate analysis (HR=2.21 (0.77-6.37), p=0.1; Supplementary Table 
6), because PSA levels were higher in patients with DDR defects (median 290 versus 
77 ng/mL, p=0.005, ranksum test). 
For eleven patients, plasma cfDNA was collected after CRPC progression. 7/9 patients 
with detectable ctDNA post-progression developed either an AR amplification or 
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mutation (Fig. 4; Supplementary Table 4 and Supplementary Fig. 7). In general, few 
changes were detected outside of the AR, although one patient (who did not develop an 
AR alteration) exhibited a hotspot CTNNB1 missense mutation at time of CRPC 
progression that was not identified in his diagnostic tissue sample (Fig. 4). Only one 
patient (17-111) demonstrated marked genomic differences between his diagnostic and 
CRPC specimens, however a shared PTEN stopgain mutation confirmed shared clonal 
ancestry. 
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Discussion 
Plasma ctDNA is abundant in most patients with treatment-naïve de novo mCSPC, 
providing additional insight into metastatic disease beyond that available from prostate 
biopsy. However, ADT exposure prior to blood collection significantly reduced ctDNA 
abundance, thereby impairing detection of clinically-relevant somatic alterations. Since 
ctDNA originates from apoptosis of cancer cells [22,23], a transient spike in ctDNA 
fractions a few hours after therapy initiation remains possible. Furthermore, ADT type 
(e.g. degarelix versus goserelin) differentially impacts the rate at which castrate 
testosterone is achieved, and may be related to the rate of ctDNA decline. We have also 
not assessed whether the biopsy procedure impacts ctDNA or non-malignant cfDNA 
release. Nevertheless, our data suggests that in order for ctDNA to guide treatment 
intensification in mCSPC, blood collection timing (relative to ADT initiation) warrants 
careful consideration. 
Particularly high ctDNA levels were observed in patients with visceral metastases, 
consistent with mCRPC where ctDNA fractions correlate with clinical prognostic markers 
[9–11]. Therefore, clinical metrics of proliferative tumour volume may help guide 
implementation of ctDNA assays in mCSPC. Also similar to mCRPC [12], somatic 
mutations identified in ctDNA were highly concordant with matched tissue biopsies. 
However, while there were cases where ctDNA proved more informative than tissue 
biopsy (for detection of driver gene alterations), the opposite was also true as some 
patients had low ctDNA levels. Technological advances continue to improve detection 
sensitivity for ultra-rare mutations in cfDNA [24], but common PCa copy number 
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alterations such as PTEN or CHD1 deletion remain undetectable when ctDNA 
constitutes a few percent of total cfDNA. Many of the alterations identified by either 
cfDNA or tissue sequencing alone have clinical relevance, from DDR gene defects and 
potential sensitivity to PARPi or immunotherapy [25,26], to TP53 and SPOP mutations 
that infer poor and favourable prognosis, respectively [10,27,28]. Therefore, the optimal 
approach for correlative studies or biomarker development in the de novo mCSPC 
setting should incorporate both tissue and plasma analyses, or risk undersampling 
disease. 
De novo mCSPC is poorly characterized since sequencing efforts have focused on 
either localized disease or mCRPC. In our study, the similarity between primary tissue 
and ctDNA may suggest that de novo mCSPC is a highly clonal disease at diagnosis, 
although follow-up studies are required to confirm this hypothesis. In localized PCa, 
intra-tumour heterogeneity is common, and truly independent tumour foci can arise 
within the same prostate [29,30]. It is possible that de novo mCSPC represents later 
stage disease, after the most aggressive tumour clone expands and predominates. 
Alternatively, it may represent a different disease trajectory, characterized by 
emergence of a singularly aggressive clone that rapidly proliferates. Regardless, de 
novo mCSPC is characterized by aggressive genomics including frequent TP53 and 
DDR gene mutations; this appears distinct from localized disease, but different 
sequencing and analysis approaches between studies prevent definitive conclusions. 
Among patients who progressed to CRPC, ctDNA at progression yielded highly similar 
profiles to their CSPC counterpart, suggesting that de novo mCSPC is primed for 
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therapy resistance. Future studies assessing larger patient numbers and a broader 
range of somatic alterations are required. 
To maintain cost-efficiency, we captured a small fraction of the genome and did not 
perform ultra-deep sequencing (i.e. ~10,000x). Some samples with apparent low tumour 
content may harbour somatic alterations at high variant frequency outside the panel, or 
conversely harbour alterations below our detection sensitivity. The unavoidable 
sampling bias associated with TRUS-guided needle biopsy may account for mutations 
detected only in ctDNA. Future studies could instead assess saturation template 
biopsies. Finally, given the level of noise associated with FFPE tissue-derived copy 
number profiles, comparisons with ctDNA-derived copy number alterations were limited. 
Conclusions 
Plasma ctDNA fractions are elevated in de novo mCSPC, especially in patients with 
visceral metastases. However, exposure to ADT compromises the potential utility of 
ctDNA. When measurable, ctDNA defines the driver alterations in de novo mCSPC, but 
combined use of ctDNA and primary tissue is optimal for assessing molecular subtype 
and could aid targeted therapy implementation in a precision oncology framework. 
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Tables and Figures 
Table 1. Clinical characteristics at diagnosis with de novo metastatic castration-sensitive 
prostate cancer (mCSPC). IQR = interquartile range; ADT = androgen deprivation 
therapy, AR = androgen receptor. *Patients enrolled in a blinded study. 
Median age at diagnosis (IQR) 68 (60-76)
Median PSA at diagnosis (IQR) 110 (32-280)
Gleason grade group
1 1 (2%)
2 0 (0%)
3 3 (6%)
4 6 (11%)
5 38 (72%)
Unknown 5 (9%)
Metastatic extent of disease at diagnosis
Lymph node only 5 (9%)
Regional 2
Non-regional 3
Bone 40 (75%)
Lung 6 (11%)
Liver 2 (4%)
Initial therapy regimen post-diagnosis
ADT only 14 (26%)
ADT + docetaxel (without AR targeted therapy) 18 (34%)
ADT + AR targeted therapy* 9 (17%)
ADT + docetaxel + AR targeted therapy* 8 (15%)
Unknown** 4 (8%)
Patients with cfDNA collected prior to ADT initiation 67%
Patients with cfDNA collected post ADT initiation (range in days) 33% (1-49)
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Figure 1. Circulating tumour DNA (ctDNA) abundance and impact of androgen 
deprivation therapy (ADT). A) Bar plot illustrating the percentage of cell-free DNA 
(cfDNA) that is tumour-derived (i.e. the ctDNA%) for each patient. Blue bars reflect 
patients that were entirely treatment-naïve at time of blood collection; red bars indicate 
those exposed to short term ADT. Key clinical variables at diagnosis are indicated in the 
matrix below the bar plot. B) Bar plot illustrating ctDNA fraction decline in serial blood 
collections after commencement of ADT (see also Supplementary Fig. 1). C) 
Proportion of patients with detected ctDNA, based on clinical variables. PSA = prostate 
specific antigen; Bx = biopsy; dx = diagnosis. 
ct
D
N
A%
ct
D
N
A%
No prior ADT
Days after ADT
Days after ADT
10
50
5
10
84
1
11
00
8
10
58
6
10
56
5
10
57
1
TR
E-
6
TR
E-
5
TR
E-
4
Metastases
Visceral
No visceral
Grade group
1 - 4
5
PSA
0 - 50
50 - 250
250+
Age at dx
40 - 70
70 - 90
8
26
10
37
16
19
17
28
24
0 20 40 1008060
Node
Bone
Lung
Liver
Tissue Bx
Grade group
PSA
PSA:Bone metastases: 0 - 50None 50 - 2501 - 4 250+5 or more
M
et
as
ta
se
s
% of patients
n
p = 0.02, ranksum test
ctDNA detected in 26 / 35 (74%)
Median = 11%
ctDNA detected in 10 / 17 (59%)
Median = 1%
80
70
60
50
40
30
20
10
0
80
70
60
50
40
30
20
10
0
11
33
1
11
51
6
10
85
0
17
-0
68
11
26
3
11
30
3
17
-0
41
11
05
0
10
50
5
10
05
4
11
30
2
11
36
4
10
84
1
11
00
8
11
39
9
11
42
1
17
-3
01
17
-1
50
11
16
7
11
49
0
11
51
5
11
39
8
11
33
9
11
28
0
10
56
5
86
96
11
07
9
90
19
10
05
7
10
20
7
11
08
1
11
19
9
11
23
0
11
48
9
16
-0
02
17
-1
54
10
58
6
17
-2
75
10
96
8
17
-0
63
17
-0
89
17
-2
70
10
57
1
17
-1
70
17
-3
00
90
53
17
-0
15
17
-1
33
17
-1
11
10
99
0
99
28
91
55
15
0 0
1
0 0 0 0 0 0
2% 0.5%
0
4
3 27119 19 86 70 40102 3488 20 86
4
7
8 15
4 1
19
7 2
21222327272828313449
A
B C
4 3 35 4 4 4 4 43 5 1 55 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 555 5 5 55 5 5 5 5
ctDNA%: 30 - 100 2 - 30
!  25
0
1
10
100
ct
DN
A 
VA
F 
%
lo
g 
sc
al
e
11
51
6
10
85
0
17
-0
68
11
26
3
11
30
3
11
05
0
10
05
4
11
30
2
11
36
4
11
39
9
17
-1
50
11
51
5
11
39
8
10
56
5
10
05
7
11
08
1
11
19
9
17
-1
54
17
-2
75
17
-0
63
17
-0
15
17
-1
11
10
99
0
99
28
91
55
100
10
1
0
Ti
ss
ue
 V
AF
 %
lo
g 
sc
al
e
TP53
mt.
FOXA1
mt.
SPOP
mt.
CHD1
deep del.
PIK3CA
mt.
KMT2C
mt.
KDM6A
mt.
ZFHX3
mt.
APC
mt.
BRCA2
mt.
KMT2D
mt.
AR
amp.
AR
mt.
Alteration
0
15
30
45
55
Al
te
ra
tio
n 
fre
qu
en
cy
 (%
) ***
*
* * * *
***
***
Localized PCa, TCGA PanCancer Atlas 2018
De novo mCSPC
mCRPC, Robinson et al., Cell 2015
25 8 6 6 5 5 4 4 4 4 3 0 0
A
Prior ADT
no
 ti
ss
ue
no
 ti
ss
ue
no
 ti
ss
ue
no
 ti
ss
ue
no
 c
tD
N
A
no
 c
tD
N
A
no
 c
tD
N
A
no
 c
tD
N
A
no
 c
tD
N
A
no
 c
tD
N
A
no
 c
tD
N
A
0
1
10
100
ct
DN
A 
VA
F 
%
lo
g 
sc
al
e
10
85
0
11
05
0
11
30
2
10
84
1
11
00
8
11
49
0
11
33
9
90
19
10
96
8
17
-1
70
11
36
3
100
10
1
0
Ti
ss
ue
 V
AF
 %
lo
g 
sc
al
e
ATM
ATR
BRCA2 somatic
BRCA2 germline
CDK12
MSH2
RAD51C
Prior ADT
no
 c
fD
N
A
no
 c
tD
N
A
Tissue 
only
ctDNA 
only
Tissue & 
ctDNA
1x low ctDNA (2%)
3x no ctDNA[
2x not detected
3x no biopsy[
0
50
100
ct
DN
A No Prior ADT
Tu
m
ou
r 
co
nt
en
t 
(%
)
11
33
1
11
51
6
10
85
0
17
-0
68
11
26
3
11
30
3
17
-0
41
11
05
0
10
50
5
10
05
4
11
30
2
11
36
4
10
84
1
11
00
8
11
39
9
11
42
1
17
-3
01
17
-1
50
11
16
7
11
49
0
11
51
5
11
39
8
11
33
9
11
28
0
10
56
5
86
96
11
07
9
90
19
10
05
7
10
20
7
11
08
1
11
19
9
11
23
0
11
48
9
16
-0
02
50
100
Ti
ss
ue
Prior ADT
17
-1
54
10
58
6
17
-2
75
10
96
8
17
-0
63
17
-0
89
17
-2
70
10
57
1
17
-1
70
17
-3
00
90
53
11
36
3
17
-0
15
17
-1
33
17
-1
11
10
99
0
99
28
91
55
0
5
10
ct
DN
A
M
ut
at
io
n 
co
un
t
14 17
1
5
10
Ti
ss
ue
B
Detection of TP53 mutations Detection of DDR gene mutations
TP53 mutation detection
in patients without prior ADT:
C D
3 2 2 2 2 4 5 3 7 6
10 10
0.5 1
!  26
Figure 2. Combined analysis of circulating tumour DNA (ctDNA) and primary tissue 
reveals aggressive genomic features. A) Frequency of recurrent somatic alterations in 
de novo metastatic castration-sensitive prostate cancer (mCSPC) as compared to 
localized prostate cancer (PCa) and metastatic castration-resistant prostate cancer 
(mCRPC). Note that sequencing platforms and bioinformatic approaches differ between 
each study, limiting the conclusions that can be drawn by study-to-study comparison. B) 
Bar plots demonstrating tumour content in tissue compared to matched ctDNA (upper 
panel), and somatic mutation count as derived from these samples (lower panel); 
stratified by exposure to androgen deprivation therapy (ADT). C) Concordance of TP53 
mutation detection between matched samples. Pie chart indicates proportion of TP53 
mutations detected by each assay in ADT-naïve patients. D) Concordance of DNA 
damage repair (DDR) gene calls. mt. = mutation; deep del. = deep deletion; amp. = 
amplification. 
!  27
Figure 3. DNA damage repair (DDR) gene defects are associated with earlier 
progression to castration-resistant prostate cancer (CRPC). A) Kaplan-Meier plot of time 
to CRPC from ADT initiation in patients with and without deleterious DDR gene 
alterations. B) Kaplan-Meier plot showing the association of ctDNA fraction and time to 
CRPC from ADT initiation. C) Swimmers plot of time to CRPC progression from 
diagnosis, stratified by DDR gene status. ADT = androgen deprivation therapy; AR = 
androgen receptor targeted therapy; DOC = docetaxel chemotherapy. 
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Figure 4. Genomic changes at progression to castration-resistant prostate cancer 
(CRPC). Oncoprint illustrating similarities between matched castrate-sensitive (S) and 
castrate-resistant (R) collections, with the exception of the AR gene. Copy number 
alterations only included for the AR gene.
